Role of serum high mobility group box 1 in hematological malignancies complicated with systemic inflammatory response syndrome and effect of recombinant thrombomodulin

References

• Abraham E, Arcaroli J, Carmody A, et al. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000;165:2950–2954.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang H, Tracey KJ. HMGB1 rediscovered as a cytokine. Shock 2001;15:247–253.
   PubMed Web of Science ®Google Scholar
• Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005;94:975–979.
   PubMed Web of Science ®Google Scholar
• Huang LF, Yao YM, Dong N, et al. Association of high mobility group box-1 protein levels with sepsis and outcome of severely burned patients. Cytokine 2011;53:29–34.
   PubMed Web of Science ®Google Scholar
• Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5:31–41.
   PubMed Web of Science ®Google Scholar
• Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC):diagnostic criteria of the international society of thrombosis and hemostasis (ISTH) and of the Japanese ministry of health and welfare for overt DIC. Am J Hematol 2003;74:17–22.
   PubMed Web of Science ®Google Scholar
• American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864–874.
   PubMed Web of Science ®Google Scholar
• Fukami A, Adachi H, Yamaguchi S, et al. Factors associated with serum high mobility group box 1(HMGB1) levels in general population. Metabolism 2009;58:1688–1693.
   PubMed Web of Science ®Google Scholar
• Abeyama K, DStren M, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005;115:1267–1274.
   PubMed Web of Science ®Google Scholar
• Meyer A, Staratschek-Jox A, Springwald A, et al. Non-Hodgkin lymphoma expressing high levels of the danger-signaling protein HMGB1. Leuk Lymphoma 2008;49:1184–1189.
   PubMed Web of Science ®Google Scholar
• Gibot S, Massin F, Cravoisy A, et al. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 2007;33:1347–1353.
   PubMed Web of Science ®Google Scholar
• Yasuda T, Ueda T, Takeyama Y, et al. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 2006;33:359–363.
   PubMed Web of Science ®Google Scholar
• Nomura S, Fujita S, Ozasa R, et al. The correlation between platelet activation markers and HMGB1 in patients with disseminated intravascular coagulation and hematologic malignancy. Platelets 2011;22:396–397.
   PubMed Web of Science ®Google Scholar
• Kang R, Tang DL, Cao LZ, et al. High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor alpha in leukemic cell. Zhonghua Er Ke Za Zhi 2007;45:329–333.
   PubMedGoogle Scholar
• Liu L, Yang M, Kang R, et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011;25:23–31.
   Google Scholar
• Esmon CT. The role of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743–4746.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Kusumoto H, Deyashiki Y, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987;6:1981–1997.
   PubMed Web of Science ®Google Scholar
• Zushi M, Gomo K, Yamamoto S, et al. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989;254:10351–10353.
   Google Scholar
• Wang H, Bloom O, Zhang M, et al. HMGB-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248–251.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Kosugi S, Miura I, et al. Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin. Thromb Res 2011;127:603–604.
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Togitani K, Komatsu N, et al. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010;45:783–785.
   PubMed Web of Science ®Google Scholar
• Sakai M, Ikezoe T, Bandobashi K, et al. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010;45:803–805.
   PubMed Web of Science ®Google Scholar
• Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003;101:2654–2660.
   Web of Science ®Google Scholar
• Luft T, Dietrich S, Falk C, et al. Steroid-refractory CVHD: T-cell attack within a vulnerable endothelial system. Blood 2011; 118:1685–1692.
   PubMed Web of Science ®Google Scholar